ULTRAGENYX PHARMACEUTICAL INC. Net Income (Loss) Available to Common Stockholders, Basic
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Net Income (Loss) Available to Common Stockholders, Basic of -$71.29 million for the 3-month period ending 2016-12-31, per its 10-K filed 2017-02-17.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2017-02-17
- ULTRAGENYX PHARMACEUTICAL INC. net income (loss) available to common stockholders, basic for the quarter ending 2016-12-31 was -$71.29M.
- ULTRAGENYX PHARMACEUTICAL INC. net income (loss) available to common stockholders, basic for the quarter ending 2016-09-30 was -$64.91M.
- ULTRAGENYX PHARMACEUTICAL INC. net income (loss) available to common stockholders, basic for the quarter ending 2016-06-30 was -$56.92M.
- ULTRAGENYX PHARMACEUTICAL INC. net income (loss) available to common stockholders, basic for the quarter ending 2016-03-31 was -$52.76M.
- ULTRAGENYX PHARMACEUTICAL INC. net income (loss) available to common stockholders, basic for fiscal 2016 was -$245.87M.
- ULTRAGENYX PHARMACEUTICAL INC. net income (loss) available to common stockholders, basic for fiscal 2015 was -$145.62M.
- ULTRAGENYX PHARMACEUTICAL INC. net income (loss) available to common stockholders, basic for fiscal 2014 was -$64.61M.
- ULTRAGENYX PHARMACEUTICAL INC. net income (loss) available to common stockholders, basic for fiscal 2013 was -$50.29M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2016-12-31 | -$71.29M 10-K · filed 2017-02-17 | -$136.19M derived: sum of 2 quarters · filed 2017-02-17 | -$193.12M derived: sum of 3 quarters · filed 2017-02-17 | -$245.87M 10-K · filed 2017-02-17 |
| 2016-09-30 | -$64.91M 10-K · filed 2017-02-17 | -$121.83M derived: sum of 2 quarters · filed 2017-02-17 | -$174.59M derived: sum of 3 quarters · filed 2017-02-17 | -$229.81M derived: sum of 4 quarters · filed 2017-02-17 |
| 2016-06-30 | -$56.92M 10-K · filed 2017-02-17 | -$109.68M derived: sum of 2 quarters · filed 2017-02-17 | -$164.90M derived: sum of 3 quarters · filed 2017-02-17 | -$204.13M derived: sum of 4 quarters · filed 2017-02-17 |
| 2016-03-31 | -$52.76M 10-K · filed 2017-02-17 | -$107.98M derived: sum of 2 quarters · filed 2017-02-17 | -$147.21M derived: sum of 3 quarters · filed 2017-02-17 | -$177.00M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-12-31 | -$55.22M 10-K · filed 2017-02-17 | -$94.45M derived: sum of 2 quarters · filed 2017-02-17 | -$124.24M derived: sum of 3 quarters · filed 2017-02-17 | -$145.62M 10-K · filed 2017-02-17 |
| 2015-09-30 | -$39.23M 10-K · filed 2017-02-17 | -$69.02M derived: sum of 2 quarters · filed 2017-02-17 | -$90.40M 10-Q · filed 2015-11-10 | -$107.14M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | -$29.79M 10-K · filed 2017-02-17 | -$51.17M 10-Q · filed 2015-08-14 | -$67.90M derived: sum of 3 quarters · filed 2017-02-17 | -$83.75M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | -$21.38M 10-K · filed 2017-02-17 | -$38.12M derived: sum of 2 quarters · filed 2017-02-17 | -$53.97M derived: sum of 3 quarters · filed 2017-02-17 | -$67.55M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | -$16.74M 10-K · filed 2016-02-26 | -$32.59M derived: sum of 2 quarters · filed 2016-02-26 | -$46.17M derived: sum of 3 quarters · filed 2016-02-26 | -$64.61M 10-K · filed 2017-02-17 |
| 2014-09-30 | -$15.85M 10-K · filed 2016-02-26 | -$29.43M derived: sum of 2 quarters · filed 2016-02-26 | -$47.87M 10-Q · filed 2015-11-10 | -$66.54M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | -$13.59M 10-K · filed 2016-02-26 | -$32.02M 10-Q · filed 2015-08-14 | -$50.69M derived: sum of 3 quarters · filed 2016-02-26 | -$63.28M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | -$18.44M 10-K · filed 2016-02-26 | -$37.10M derived: sum of 2 quarters · filed 2016-02-26 | -$49.69M derived: sum of 3 quarters · filed 2016-02-26 | -$60.52M derived: sum of 4 quarters · filed 2016-02-26 |
| 2013-12-31 | -$18.66M 10-K · filed 2015-03-27 | -$31.25M derived: sum of 2 quarters · filed 2015-03-27 | -$42.08M derived: sum of 3 quarters · filed 2015-03-27 | -$50.29M 10-K · filed 2016-02-26 |
| 2013-09-30 | -$12.59M 10-K · filed 2015-03-27 | -$23.42M derived: sum of 2 quarters · filed 2015-03-27 | -$31.62M 10-Q · filed 2014-11-10 | |
| 2013-06-30 | -$10.83M 10-K · filed 2015-03-27 | -$19.03M 10-Q · filed 2014-08-11 | ||
| 2013-03-31 | -$8.21M 10-K · filed 2015-03-27 | |||
| 2012-12-31 | -$19.56M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |